Immunotherapy and temozolomide for melanoma brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have melanoma that is stage IV (advanced) confirmed by pathology/biopsy.
- You have at least one brain metastasis seen on brain MRI that is measurable (at least 10 mm) and clearly getting worse.
- You are not planned to receive stereotactic (focused) brain radiation, and you are not already planned for other cancer treatments or brain radiation during the study.
- You must have been off cancer treatment for at least 4 weeks before starting (chemotherapy, immunotherapy, targeted drugs, or radiation).
- Your blood counts and organ tests must be high enough (neutrophils and platelets and hemoglobin) and liver/kidney function must be within allowed limits, including adequate albumin (a protein).
- If you have brain swelling and need steroids, your steroid dose must be stable (and typically not higher than 4 mg per day unless the study doctor approves).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of therapy where your own immune cells (called T cells) are taken, specially trained to attack your melanoma, and then given back into the fluid around your brain and spinal cord. The goal is to see if this can help treat melanoma that has spread to that area.
This trial tests a combination of a drug that stops blood vessel growth (bevacizumab), immunotherapy, and focused radiation to treat melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
Hear when a new Clinical Stage IV Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.